CME vs Marex
CME and MRX side by side, both in security & commodity brokers, dealers, exchanges & services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CME and MRX compare
Marex grew revenue faster over the last twelve months (26.9% versus 9.0% for CME).
CME pays a dividend yielding 3.6%; Marex does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CME | MRX |
|---|---|---|
| Size and price | ||
| Market cap | $114B | – |
| Share price | $317.97 | $70.72 |
| Change, 1 year | 13.7% | 103% |
| Change, 5 years | 42.4% | – |
| Beta (5Y) | 0.36 | 0.46 |
| Employees | 3,875 | 3,109 |
| StockData Score | ||
| Total score | 9 | 9 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 1 (better) | 0 |
| Valuation | ||
| P/E | 26.1× | – |
| P/S | 16.3× | – |
| P/B | 4.3× | – |
| EV/EBITDA | 24.4× | – |
| P/FCF | 26.3× | – |
| PEG | 1.78 | – |
| FCF yield | 3.8% | – |
| Fair value | $262.19 | – |
| Margin of safety | −21.3% | – |
| Growth | ||
| Revenue growth (TTM) | 9.0% | 26.9% (better) |
| Revenue growth, 5Y average | 6.0% | – |
| Net income growth (TTM) | – | 43.6% |
| EPS growth (TTM) | 18.1% | 41.9% (better) |
| EPS growth, 5Y average | 13.7% | – |
| Profitability | ||
| Operating margin | 65.7% | – |
| Net margin | – | 14.5% |
| FCF margin | 62.1% (better) | 32.3% |
| Return on equity | – | 28.7% |
| Return on invested capital | 14.1% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.17 (better) |
| Net debt / EBITDA | – | −2.22 |
| Current ratio | 1.02 | 1.09 (better) |
| Altman Z-score | 0.59 | – |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | 3.6% | – |
| Payout ratio | – | 18.9% |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | −3.3% | – |
| Shareholder yield | 3.6% | – |
| Ownership | ||
| Held by institutions | 90.0% | 77.6% |
| Held by insiders | 0.34% | 8.4% |
| Insider net buying, 12 months | −$33.6M | −$19.8M (better) |
| Superinvestors holding | 5 | – |
| Short interest, % of float | 1.5% | 3.3% |
Go deeper
- CME stock overview
- CME income statement
- CME valuation and score
- MRX stock overview
- MRX income statement
- MRX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.